Summary of Biopharma Industry Conference Call Industry Overview - The focus for 2026 in the Biopharma sector is shifting back to fundamentals as policy overhangs diminish, particularly regarding drug pricing dynamics [1][2][23] - Key players in the industry include major biopharma companies such as Pfizer (PFE), AstraZeneca (AZN), Eli Lilly (LLY), and Novo Nordisk [2][24] Core Insights - **Policy Changes**: The most-favored nation (MFN) drug pricing agreements signed by five biopharma companies have significantly reduced policy overhangs, leading to an expansion in P/E multiples [2][23] - **Healthcare Sector Upgrade**: The US Equity Strategists upgraded the Healthcare sector to overweight, anticipating benefits from rate cuts, supportive earnings momentum, and M&A tailwinds [3] - **M&A Environment**: An estimated $150 billion in revenue from large-cap biopharma companies will go off patent by the end of the decade, creating favorable conditions for M&A activity [10] Key Products and Pipelines - **New Product Cycles**: Focus on new products such as LLY's Orforglipron for diabesity, GILD's Yeztugo for HIV PREP, and JNJ/PTGX's Ico for psoriasis [5] - **Pipeline Catalysts**: Significant upcoming data releases include LLY's obesity and T2D data, Novo's obesity data, and various trials across therapeutic areas such as Alzheimer's, oncology, immunology, and cardiology [6][12] Financial Metrics - **Valuation Context**: The relative valuation for the Healthcare sector remains in the bottom 6th percentile of historical levels over the last 30 years, indicating potential for growth [3] - **Earnings Projections**: Companies like LLY and GILD are projected to see significant earnings growth, with LLY's EPS expected to rise by 10% [13][19] Additional Considerations - **Legal Landscape**: The SCOTUS ruling on IEEPA tariffs and ongoing investigations could impact future policy and pricing strategies [2][25][30] - **FDA Uncertainty**: Changes in FDA leadership and potential delays in drug approvals due to workforce reductions are areas of concern as the industry moves into 2026 [33][34] - **CMS Pilot Programs**: Proposed drug pricing pilot programs by CMS could influence market dynamics, particularly for companies that have signed MFN deals [32] Conclusion - The Biopharma industry is poised for a shift towards fundamentals in 2026, with significant opportunities arising from new product launches, M&A activity, and favorable policy changes. However, ongoing legal and regulatory uncertainties remain critical factors to monitor.

Core Viewpoint - The healthcare sector is anticipated to potentially rebound in 2026, with several attractive stocks identified for investment, including AbbVie, Eli Lilly, and Intuitive Surgical. AbbVie - AbbVie is recognized as a reliable dividend payer, boasting 54 consecutive payout increases, qualifying it as a Dividend King [3] - The company reported third-quarter revenue of $15.8 billion, reflecting a 9% increase year-over-year [4] - AbbVie's product portfolio includes key drugs such as Vraylar, Botox Therapeutics, Qulipta, Skyrizi, and Rinvoq, which are expected to drive future growth [6][8] - Skyrizi is projected to become the second best-selling drug globally by 2030, with estimated sales of $26.6 billion [7] Eli Lilly - Eli Lilly's third-quarter revenue reached $17.6 billion, marking a significant 54% year-over-year growth [9] - The company is leveraging tirzepatide, marketed as Zepbound and Mounjaro, to sustain its growth trajectory, alongside promising pipeline candidates like orforglipron [10] - Eli Lilly is diversifying its portfolio, with recent launches in oncology, including Jaypirca for mantle cell lymphoma and Inluriyo for breast cancer [13] - The company's strategic investments in artificial intelligence and other therapeutic areas position it favorably for future growth [14] Intuitive Surgical - Intuitive Surgical faces challenges from tariffs and increased competition, particularly from Medtronic's Hugo system [15] - Despite these challenges, the company maintains a strong economic moat with 10,763 da Vinci systems installed, which creates high switching costs for customers [16] - The da Vinci system has over two decades of clinical evidence supporting its effectiveness, allowing Intuitive Surgical to command significant pricing power [18] - The company is expected to benefit from label expansions and increased procedure volumes, which will enhance revenue and margins over time [19]

Core Insights - Building wealth through dividends requires a strategy that goes beyond simply chasing high yields, emphasizing the importance of meaningful current income and consistent dividend growth supported by sustainable business fundamentals [1] Group 1 - The path to wealth accumulation involves a combination of current income and dividend growth [1] - Sustainable business fundamentals are crucial for supporting dividend growth [1]

Core Insights - The rise of artificial intelligence (AI) has significantly impacted the stock market, benefiting technology companies and growth-oriented investments while putting pressure on dividend-focused funds like the Schwab U.S. Dividend Equity ETF (SCHD) [2][4] Group 1: ETF Overview - The Schwab U.S. Dividend Equity ETF tracks the Dow Jones U.S. Dividend 100 Index, focusing on high-quality U.S. firms with consistent dividend payments and strong financial ratios [3] - The ETF currently offers a trailing yield of approximately 3.8%, which is higher than the S&P 500's payout, and has a low expense ratio of 0.06% [3] Group 2: Performance Analysis - The SCHD has underperformed during the AI boom, with year-to-date total returns being near flat or slightly positive, while tech-focused funds like the Invesco QQQ Trust have seen stronger gains [7][8] - The ETF's portfolio is heavily weighted towards stable dividend payers in sectors such as energy (19%), consumer discretionary (18%), and healthcare (16%), with limited exposure to high-growth AI leaders [6][8] Group 3: Market Dynamics - The AI surge has concentrated market gains among a few mega-cap tech stocks, which prioritize reinvesting profits into growth rather than paying dividends, thus limiting their representation in SCHD's portfolio [5] - The equity risk premium has approached zero in 2025, indicating potential overvaluation reminiscent of the dot-com era [8]

Core Insights - AbbVie's stock has recently slipped below its 50-day simple moving average (SMA), indicating recent selling pressure, despite a recovery after a post-earnings dip [1][2][8] - The company has successfully launched new drugs, Skyrizi and Rinvoq, which are expected to drive revenue growth in the coming years, offsetting declines from Humira and the Aesthetics unit [5][7][29] Financial Performance - AbbVie reported combined sales of Skyrizi and Rinvoq at $18.5 billion for the first nine months of 2025, with expectations to exceed $25 billion in 2025 and $31 billion by 2027 [6][7] - The oncology segment generated revenues of $5.0 billion in the first nine months of 2025, a 2.7% year-over-year increase, driven by new drug sales [10] - Neuroscience drug sales increased by 20.3% to nearly $7.8 billion in the same period, supported by products like Botox Therapeutic and Vraylar [11] Market Challenges - Humira's sales have declined over 50% in the first nine months of 2025 due to biosimilar erosion, significantly impacting overall revenue [15] - The Aesthetics segment has seen a 7.4% decline in global sales, with Juvederm and Botox Cosmetics sales falling by 16.7% and 7.4%, respectively [16][17] Strategic Initiatives - AbbVie has been actively pursuing acquisitions to enhance its early-stage pipeline, completing over 30 M&A transactions since early 2024 [14] - The company recently settled patent litigation for Rinvoq, extending its patent exclusivity to 2037, which is expected to bolster its revenue stream [9] Future Outlook - AbbVie anticipates returning to mid-single-digit revenue growth in 2025, driven by strong performances from Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29] - The company has increased its quarterly cash dividend by 5.5%, reflecting confidence in future growth despite recent estimate declines [30]

Group 1: McDonald's Corporation - McDonald's continues to show strong performance with a notable increase in global comparable sales, which rose by 10.3% in the last quarter [1] - The company is focusing on digital innovation and menu enhancements to drive customer engagement and sales growth [1] - McDonald's expansion strategy includes opening new locations in international markets, contributing to overall revenue growth [1] Group 2: Walmart Inc - Walmart reported a 6.2% increase in total revenue, reaching $152.9 billion for the last quarter, driven by strong e-commerce sales [1] - The company is investing heavily in technology to improve supply chain efficiency and enhance customer experience [1] - Walmart's grocery segment remains a key growth driver, with a significant increase in online grocery orders [1] Group 3: AbbVie Inc - AbbVie experienced a revenue increase of 8.5%, totaling $14.5 billion, primarily due to strong sales of its immunology and oncology products [1] - The company is actively pursuing strategic acquisitions to diversify its product portfolio and enhance growth prospects [1] - AbbVie is focusing on research and development to bring new therapies to market, which is expected to drive future revenue growth [1]

Core Insights - The article emphasizes the importance of dividend investing, highlighting that the best dividend stocks not only provide consistent payouts but also increase their dividends over time, benefiting long-term shareholders [1] Group 1: Dividend Growth Leaders - Johnson & Johnson (JNJ) has a 2.54% yield and has increased dividends for 62 consecutive years, supported by a diversified portfolio in healthcare [5][6] - Coca-Cola (KO) boasts a 2.87% yield with 63 years of dividend increases, demonstrating strong operational performance and pricing power [8][9] - Procter & Gamble (PG) leads with 68 consecutive years of dividend increases, offering a 2.96% yield and showcasing operational excellence [11][12] - AbbVie (ABBV) has the fastest dividend growth in this ranking, with a recent 5.5% increase, bringing its yield to 2.94% [15][16] - Realty Income (O) offers a unique monthly dividend structure with a 5.62% yield, supported by a strong rent recapture rate and a long history of dividend increases [18][19] Group 2: Financial Performance - JNJ reported Q3 2025 EPS of $2.80, with revenue of $24.0 billion, and raised its full-year guidance, indicating confidence in growth [6][7] - Coca-Cola's Q3 2025 EPS was $0.86, with revenue of $12.5 billion and a stable operating margin of 32%, reflecting its ability to pass costs to consumers [9][10] - Procter & Gamble's Q1 fiscal 2026 EPS was $1.95, with revenue of $22.4 billion and a free cash flow of $5.4 billion, indicating strong cash generation [12][13] - AbbVie's Q3 2025 EPS was $1.86, with revenue of $15.8 billion, and management raised its EPS guidance for the full year [16][17] - Realty Income's Q3 2025 AFFO reached $1.08 per share, with a full-year guidance increase and a quarterly revenue growth of 10.3% year-over-year [19][20]

Summary of Conference Call Company and Industry - The conference call primarily discusses Salesforce, a leading company in the cloud-based software industry, particularly focusing on customer relationship management (CRM) and AgenTech solutions. Key Points and Arguments 1. **Strong Financial Performance**: Salesforce reported its best Q3 results in company history, with bookings growing significantly, marking the fastest growth in three and a half years [1][2] 2. **Net New ACV Growth**: The company emphasized the importance of net new Annual Contract Value (ACV), which is the difference between bookings and attrition. This metric is crucial as it indicates future revenue acceleration [1][2] 3. **Future Revenue Projections**: Salesforce aims to reach $60 billion in fiscal year 2030, driven by unprecedented demand and a robust sales pipeline [4] 4. **Agentforce Product Success**: The Agentforce product has shown remarkable growth, achieving $550 million in ARR, with a 450% year-on-year increase. Over 18,000 customers are using Agentforce, with 9,500 paying customers [10][12] 5. **Customer Engagement**: More than 50% of bookings in Q3 came from existing customers who are increasing their usage of Agentforce, indicating strong customer satisfaction and engagement [12][14] 6. **AgenTech Market Potential**: Salesforce is positioning itself as a leader in the AgenTech space, with expectations that most of its 1.2 million customers will adopt its platform for digital labor solutions, potentially multiplying their business with Salesforce by three to four times [34][36] 7. **AI Integration**: The call highlighted the importance of integrating AI into enterprise solutions, emphasizing that Salesforce's existing data and execution capabilities provide a competitive advantage in scaling AI solutions [46][60] 8. **Sales Capacity Increase**: Salesforce has increased its sales capacity by 23% and expects to finish the year with a 20% increase, which is crucial for meeting the growing demand for its products [78][88] 9. **Productivity Metrics**: The company focuses on three key metrics: net new ACV growth, productivity, and consumption of its products, which are essential for maintaining growth and efficiency [100][102] 10. **Customer Refilling the Tank**: The concept of customers "refilling the tank" refers to existing customers increasing their usage of Salesforce products, which shortens sales cycles and enhances productivity [111] Other Important Insights - **Pricing Strategies**: Salesforce is offering flexible pricing options, including the AgenTech Enterprise License Agreement (AELA) for customers ready to scale, and pay-as-you-go models for those wanting to experiment [71][75] - **Competitive Landscape**: Salesforce is gaining market share from competitors like Veeva in the life sciences sector, having won contracts with major pharmaceutical companies [95] - **Innovation and Product Launches**: The company continues to innovate with new products and features, such as Voice and Life Sciences Cloud, which are expected to drive further growth [90][96] This summary encapsulates the key insights from the conference call, highlighting Salesforce's strong performance, growth strategies, and market positioning in the evolving tech landscape.

Core Viewpoint - AbbVie remains attractively valued despite recent challenges, with potential for market-beating returns over the next five years [2] Valuation Metrics - AbbVie trades at 16.8 times forward earnings, lower than the healthcare sector average of 18.3 and the S&P 500 average of 22.6 [4] - The price/earnings-to-growth (PEG ratio) of 0.43 indicates that AbbVie is undervalued [4] Key Financial Data - Current stock price is $224.14 with a market cap of $398 billion [5] - The stock has a 52-week range of $164.39 to $244.81 and a gross margin of 69.68% [6] Growth Drivers - AbbVie has a diverse product lineup in neuroscience, oncology, and immunology, with Skyrizi and Rinvoq as key growth drivers [7] - These products are approved for multiple indications and will maintain patent exclusivity for at least the next five years [8] Future Prospects - AbbVie is expected to expand its product lineup through new approvals from its extensive pipeline [9] - The company will not face major patent cliffs through the end of the 2020s, supporting consistent revenue and earnings growth [8] Dividend Information - AbbVie is recognized as a Dividend King, having increased its payouts for 54 consecutive years [10] - The company's strong dividend program makes it an attractive option for income-seeking investors [11]

2025 R&D Update and ASH Data Review December 11, 2025 © Genmab 2025 This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans ...